Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging

Molecular assessment using circulating tumor DNA (ctDNA) has not been well-defined. We recruited 61 pancreatic cancer (PC) patients who underwent initial computed tomography (CT) imaging study during first-line chemotherapy. Initial molecular assessment was performed using droplet digital PCR and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Fumiaki, Suzuki, Koichi, Aizawa, Hidetoshi, Endo, Yuhei, Takayama, Yuji, Kakizawa, Nao, Kato, Takaharu, Noda, Hiroshi, Rikiyama, Toshiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036464/
https://www.ncbi.nlm.nih.gov/pubmed/36959222
http://dx.doi.org/10.1038/s41598-023-31051-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036464/
https://www.ncbi.nlm.nih.gov/pubmed/36959222
http://dx.doi.org/10.1038/s41598-023-31051-7

Ejemplares similares